Gallium nitrate in prostatic cancer: Evaluation of antitumor activity and effects on bone turnover Academic Article uri icon


MeSH Major

  • Adenocarcinoma
  • Bone Neoplasms
  • Bone and Bones
  • Gallium
  • Prostatic Neoplasms


  • Gallium nitrate, an agent known to inhibit bone resorption, was evaluated in patients with bidimensionally measurable hormone-refractory prostatic cancer. The starting dose was 200 mg/m2 iv by continuous infusion over 7 days. Two patients (10%; 95% confidence limits, 0%-22%) achieved short partial remissions of 1 and 6+ months, while seven of 23 (30%; 95% confidence limits, 14%-52%) showed a diminution of bone pain. Serial indices of bone turnover including serum calcium, phosphorus, and urinary hydroxyproline excretion showed a significant decrease at the completion of the infusion which returned to baseline prior to the next cycle. The data suggest the effect on bone was too short to produce consistent improvement. Reasons for the dissociation of pain relief and antitumor activity are discussed.

publication date

  • December 1987



  • Academic Article



  • eng

PubMed ID

  • 3308078

Additional Document Info

start page

  • 887

end page

  • 93


  • 71


  • 10